title: Modal DNA values and estramustine-binding protein (EMBP) as prognostic markers in prostatic cancer.
abstract: In this study, we have investigated the model DNA values and the expression of estramustine-binding protein (EMBP) in formalin-fixed and paraffin-embedded TUR specimens from 76 untreated patients with prostatic cancer. In addition, specimens from 13 patients were analyzed for tumour EMBP expression only. Ploidy was measured as diploid, tetraploid and non-tetraploid aneuploid or aneuploid in the near-diploid region. All patients had been referred during 1978-1981, and were subjected to TUR due to urinary obstruction. Survival data were obtained for all patients through March 1988. Statistical analyses were performed using a Cox's regression model with respect to survival and cause specific survival and correlated to the DNA pattern and the expression of EMBP. The existence of a near-diploid aneuploid cell population as well as poor differentiation grade were both statistically significantly correlated with poor survival. Near-diploid aneuploid cell lines were seen in 9/76 (12%) of the patients and were also seen in well differentiated cancers (4/17). The expression of EMBP was most abundant in the moderately differentiated cancers. However, all prostatic cancer specimens investigated were positive for the antigen. Patients with poorly differentiated carcinomas and high EMBP expression showed a tendency towards better prognosis than those with poorly differentiated carcinomas and low EMBP expression. The present patient material was, however, too small to show a statistically significant correlation between EMBP and survival.
authors.affiliation: Department of Clinical Pathology, Central Hospital, Västerås, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Nordgren
authors.forename: S
authors.initials: S
authors.lastname: Nilsson
authors.forename: S
authors.initials: S
authors.lastname: Eklöv
authors.forename: P
authors.initials: P
authors.lastname: Stattin
authors.forename: W
authors.initials: W
authors.lastname: Naining
authors.forename: T
authors.initials: T
authors.lastname: Heiden
authors.forename: L
authors.initials: L
authors.lastname: Bergkvist
authors.forename: L
authors.initials: L
authors.lastname: Karlberg
authors.forename: C
authors.initials: C
authors.lastname: Lundholm
authors.forename: B
authors.initials: B
authors.lastname: Harvig
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D014408:Biomarkers, Tumor / Q000032:analysis*; D002352:Carrier Proteins / Q000032:analysis*; D004273:DNA, Neoplasm / Q000032:analysis*; D004171:Diploidy; D004961:Estramustine; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000235:genetics* / Q000401:mortality; D029584:Prostatic Secretory Proteins
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D004273:DNA, Neoplasm; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D004961:Estramustine